Statins for the primary prevention of cardiovascular disease.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomised controlled trials
PubMed 23440795 · doi:10.1002/14651858.CD004816.pub5
What was done
This Cochrane systematic review and meta-analysis evaluated randomised controlled trials comparing statins to placebo or usual care in adults where 10% or fewer had a history of cardiovascular disease (CVD). Eligible trials required a minimum treatment duration of one year and follow-up of at least six months. Searches of CENTRAL, MEDLINE, and EMBASE were updated through January 2012 without language restrictions. Two authors independently selected trials and extracted data on all-cause mortality, composite and individual CVD/coronary events, stroke, revascularisation, lipid concentrations, and adverse events.
What was found
Eighteen RCTs (19 trial arms; 56,934 participants) were included. Statins significantly reduced all-cause mortality (OR 0.86, 95% CI 0.79 to 0.94), combined fatal and non-fatal CVD events (RR 0.75, 95% CI 0.70 to 0.81), combined fatal and non-fatal coronary heart disease events (RR 0.73, 95% CI 0.67 to 0.80), combined fatal and non-fatal stroke (RR 0.78, 95% CI 0.68 to 0.89), and revascularisation rates (RR 0.62, 95% CI 0.54 to 0.72). Total and LDL cholesterol were reduced across trials, though effect sizes showed heterogeneity. No evidence of excess serious adverse events was detected.
Why it matters
This review establishes that statin therapy delivers broad clinical benefits for primary prevention—including a significant reduction in all-cause mortality—with a favorable safety profile across diverse risk groups.
Limits
Fourteen of the 18 included trials specifically recruited populations with existing risk conditions (such as diabetes, hypertension, microalbuminuria, or dyslipidemia), and up to 10% of participants had prior CVD. Heterogeneity was present in the extent of cholesterol reduction across trials, and the abstract provides limited quantitative detail on quality-of-life and cost-effectiveness measures.
Cited by
- supports Therapeutic interventions designed to raise HDL cholesterol have failed to reduce heart disease risk, whereas interventions lowering LDL have consistently succeeded.
- supports Statin therapy reduces cardiovascular disease risk by approximately 30% to 40%.